Copay help by condition · Cancer and blood cancer · read 2026-11-08
Colorectal cancer: which charitable copay funds are open
All 2 funds we hold for Colorectal cancer are closed or at capacity right now (read 2026-11-08).
Funds fill and reopen. Use the alert below, ask the manufacturer's program for your drug (see the assistance finder), and check your state's Medicaid coverage.
If you have Medicare Part D: CMS prints the annual out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026) (Table V-2 of its CY 2027 announcement). It is a benefit parameter and applies to covered drugs under plan rules. What changes on January 1.
Swipe to read across
A copy for a patient, a clinic or a pharmacist, with each source and the date we read it.
Every fund we hold for Colorectal cancer
- Closed or at capacityColorectal Carcinoma - Medicare Access
HealthWell Foundation ·
Award level: not statedInsurance supported: not stated
The page lists the fund as Closed. Source page
- Closed or at capacityColorectal cancer
TotalAssist (Patient Advocate Foundation copay funds) ·
Award level: $5,000Insurance supported: Medicaid, Medicare, TRICARE
The page lists the fund as Closed. Source page
Drugs whose FDA label names Colorectal cancer
6 drugs. Each row quotes the sentence of the drug's FDA label (Indications and Usage, openFDA) that names the condition. A label naming a condition is not a statement that the drug is approved, effective or covered for you. Dashes in quotes are shown as hyphens. Of these, 3 have a program (in our assistance finder or on the program's own page) and 0 have a Medicare negotiated price in the CMS file; an empty cell says we found nothing in our data, not that nothing exists.
| Drug | What the FDA label says | Manufacturer program | Medicare negotiated price |
|---|---|---|---|
| Braftovi Encorafenib Every route for this drug | Colorectal Cancer (CRC) • in combination with cetuximab and fluorouracil-based chemotherapy, for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation ... Label on openFDA, read 2026-11-10 | Pfizer RxPathways (Pfizer Patient Assistance Program) | not in the CMS negotiated-price file |
| Stivarga Regorafenib Every route for this drug | Metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy. Label on openFDA, read 2026-11-10 | Bayer US Patient Assistance Foundation (program page) | not in the CMS negotiated-price file |
| Lumakras Sotorasib Every route for this drug | KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC) In combination with panitumumab, for the treatment of adult patients with KRAS G12C-mutated mCRC as determined by an FDA approved-test, who have received prior ... Label on openFDA, read 2026-11-10 | Amgen Safety Net Foundation (program page) | not in the CMS negotiated-price file |
| Fruzaqla Fruquintinib | FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and ... Label on openFDA, read 2026-11-10 | not in our assistance finder | not in the CMS negotiated-price file |
| Lonsurf Trifluridine/Tipiracil Hcl | ... metastatic colorectal cancer as a single agent or in combination with bevacizumab who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF ... Label on openFDA, read 2026-11-10 | not in our assistance finder | not in the CMS negotiated-price file |
| Tukysa Tucatinib | ... in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. Label on openFDA, read 2026-11-10 | Pfizer RxPathways (Pfizer Patient Assistance Program) Not in its current list The program's page printed this drug in an earlier list and not in its current one. | not in the CMS negotiated-price file |
Funds for costs around Colorectal cancer
These pay for a kind of cost, not a diagnosis. Each is shown with its own status.
Funds for costs around cancer and blood cancer in general: behavioral health (1 open of 2), caregiver support (0 open of 2), clinical trial costs (0 open of 1), home care (1 open of 1), named fund (0 open of 1), pain management (0 open of 1), testing (1 open of 1) and transportation (0 open of 1). Every one is listed, with its source, on the Cancer and blood cancer page.
Related conditions
Group: Cancer and blood cancer. All conditions: the condition index. Fund board for every condition: charitable copay fund status.
What changed
First read on 2026-11-08. We keep each read with its date, so a fund reopening or closing will show here as a change. Until we have a second read there is nothing to compare, and we do not guess. The read date of every source is on the changes page.
This page as data
The same facts as JSON, each fund with its source URL and read date: colorectal-cancer.json. Edition 2026-11, root 006ab9a329709cbe. See the licence page.
Questions
Is there an open charitable copay fund for Colorectal cancer?
As read on 2026-11-08, none of the 2 funds we hold for Colorectal cancer say they are open. Funds reopen, so use the alert on this page.
Which organizations run funds for Colorectal cancer?
HealthWell Foundation and TotalAssist (Patient Advocate Foundation copay funds). Each fund row on this page links to the organization's own page.
Does an open fund mean I qualify?
No. A status says whether a fund is taking applications. Eligibility, award level and which insurance it supports are each fund's own rules; where the page states them they are shown on the fund.
How current is this page?
Statuses are what each fund's own page said on the date we read it (2026-11-08). We do not promise a fund is still in that state today.